Heart valve shape may predict drug success in thick heart muscle disease
NCT ID NCT07716826
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This study looks at people with obstructive hypertrophic cardiomyopathy — a condition where the heart muscle is abnormally thick and blocks blood flow. Researchers want to see if certain abnormalities in the mitral valve or its supporting structures affect how well the drug mavacamten works. Participants are already taking mavacamten, and the study tracks changes in heart pressure and symptoms over six months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- mavacamten
- What this could lead to
- If successful, this study could help doctors predict which patients with obstructive hypertrophic cardiomyopathy will benefit most from mavacamten based on their mitral valve anatomy.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients with this condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patient with a diagnosis of HCM with significant obstruction (left intraventricular gradient at rest or during Valsalva maneuver ≥ 50 mmHg) and symptomatic (NYHA class 2 or 3) and started treatment with Mavacamten
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Inclusion Criteria : * Age ≥18 years * Patients who are informed and consent to participate * CMH with significant obstruction (left intraventricular gradient at rest or during Valsalva maneuver ≥ 50 mmHg) and symptomatic (NYHA class 2 or 3) * Patients who have started treatment with Mavacamten Exclusion Criteria: * Patients who refuse to participate in this register
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiomyopathy, hypertrophic obstructive are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.